Submacular surgery for choroidal neovascularisation
The leading cause of irreversible blindness in the Western world after the age of 55 is age-related macular degeneration (ARMD). We Why is there a difference in the results with POHS and ARMD? Firstly, many of the eyes with POHS have residual retinal pigment epithelium (RPE) beneath the fovea after removal of the neovascular complex, probably a consequence of the membrane lying between the RPE and neurosensory retina. In contrast, the neovascular complex in ARMD is intimately associated with the underlying RPE resulting in its consistent removal at the time of surgery. Without subfoveal RPE there will not be recovery of central vision. Secondly, some of the eyes with POHS have RPE removed at the time of surgical extirpation of the neovascular complex but presumably have subsequent regeneraton of the subfoveal RPE from adjacent cells.
These eyes exhibit recovery of foveal vision with fixation on an area of neurosensory retina beneath which there is no pigmented RPE. Presumably adjacent RPE has replicated, at which time it is non-pigmented, and migrated across an intact Bruch's membrane to re-establish a supportive relation with the overlying photoreceptors. This capability of RPE has recently been demonstrated in the non-human primate and pig.5 6 In eyes with ARMD, in patients who are many years older than in POHS, either senescent RPE and/or a damaged Bruch's membrane does not result in the repopulation of the denuded area of RPE created at the time of surgery. If RPE were able to repopulate this area foveal vision might recover in a substantial number of eyes.
How can we repopulate these denuded areas of RPE in ARMD which are created at the time of submacular surgery? Two approaches are currently being explored: (1) the stimulation of adjacent senescent RPE cells to divide and spread by the application of various growth factors at the time of surgery; (2) RPE transplantation with sheets of RPE cells harvested from younger donors. 7 Although the latter approach involves the transplantation of tissue into a presumed immunologically privileged site the use of foreign (that is, allogeneic) RPE cells will undoubtedly require immune suppression of the recipient, either systemically or locally, to be successful.
The advent of submacular surgery for choroidal neovascularisation has opened new avenues for the potential treatment of retinal diseases for which there is currently no effective intervention. This new era will probably see the use of pharmacological agents, retinal transplantation, and gene therapy to achieve therapeutic success.
